Companies › CUE

CUE BIOPHARMA (CUE)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001645460 · EDGAR filings · Updated 2026-07-22

CUE BIOPHARMA (CUE) has reported institutional ownership of 21.9%, with 54 institutional managers holding positions valued at $4.96M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (1)

• 2026-07-22 — D filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-15 — Insider transaction reported (Form 4)
• 2026-07-15 — Initial insider ownership filed (Form 3)
• 2026-07-10 — Insider transaction reported (Form 4)
• 2026-07-10 — Insider transaction reported (Form 4)
• 2026-07-10 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, CUE BIOPHARMA has 54 institutional holders and institutional ownership of 21.9%.

Insider activity

Insiders reported 5 transactions (5 buys, 0 sells) across 1 reporting insiders, with a net reported value of $99.7K.

Data flags from SEC filings

Related companies

PAVmed Inc (PAVM) · MINDWALK HOLDINGS CORP COM (HYFT) · Marker Therapeutics Inc (MRKR) · ELECTROCORE INC (ECOR) · SPECTRAL AI INC (MDAI) · NASUS PHARMA LTD (NSRX)